Since ICC differentiation cannot be supported solely by supplying free Kitl/KITLG [2,21], pharmacological interventions will likely require stimulation of local production of both soluble and membrane-associated Kitl/KITLG, which, as our data show, could be accomplished by IGF1 administration or GSK3i. This evidence concerns the gene KITLG and intrahepatic cholangiocarcinoma.